Dopamine

Withdrawn application: Ongentys, 12/03/2024

Retrieved on: 
Wednesday, April 3, 2024
Dopamine, DDCI, Brain, Letter, Capsule, Myenteric plexus, L-DOPA, Patient, Movement disorder, European Medicines Agency, Clinical trial, Mouth, MDS, Delayed onset muscle soreness, Movement, COMT, MDS-UPDRS, Medicine, Pharmaceutical industry

Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due.

Key Points: 
  • Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due.
  • It contains the active substance opicapone and is available as capsules to be taken by mouth.
  • t
    The application was withdrawn after the European Medicines Agency had evaluated the information from the company and had prepared questions for the company.
  • If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

Retrieved on: 
Thursday, February 29, 2024
Research, Neurology, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Therapy, Alaska Permanent Fund, Myenteric plexus, Neuron, Dopamine, IPSC, Column, Patient, Survival, DSM-IV codes, IND, Pharmaceutical industry

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.

Key Points: 
  • Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.
  • Kenai Therapeutics previously raised seed funding under the name Ryne Bio.
  • Proceeds from the financing will enable the Company to submit an IND for RNDP-001 and complete Phase 1 clinical trials, which will initiate within the year.
  • “We are proud to be able to support Kenai in its mission to advance RNDP-001 to help families and patients suffering with this devastating disease.”

Drew Barrymore Announces She’s the New Brand Ambassador for Dr. Kellyann's Breakthrough Perimenopause and Menopause Formula

Retrieved on: 
Thursday, February 29, 2024
Vitamins, Supplements, Women, Other Retail, Fitness & Nutrition, Specialty, General Health, Consumer, Health, Retail, Online Retail, Metabolism, Woman, Capsule, Shame, Multimedia, Saffron, Serotonin, Hormone, Female, Dopamine, Menopause, World Health Organization, Norepinephrine, Life, Powder, Human, Family, Insulin, MS-10, Hot, Beauty

Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.

Key Points: 
  • Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.
  • The influential voice of Drew Barrymore is helping more women than ever to feel comfortable and empowered to take control of their hormones, in a safe and natural way during perimenopause and menopause.
  • Dr. Kellyann and Drew Barrymore teamed up after Drew tried Dr. Kellyann &ME Peri + Menopause for 3 months and had incredible results.
  • To learn more about Dr. Kellyann &ME Peri + Menopause visit drkellyann.com or join the menopause conversation by following @drkellyannpetrucci across social.

InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO

Retrieved on: 
Tuesday, February 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain

InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.

Key Points: 
  • InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
  • Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
  • ," says Véronique Foutel, CEO of InBrain Pharma.
  • "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

Retrieved on: 
Wednesday, January 31, 2024
Multiple sclerosis, Movement, Poster, GM1 gangliosidoses, Neuroprotection, Enamine, Workflow, SAD, AFL, GM1, ChromeOS, Clinical trial, Research, PLOS, Neuroinflammation, Biomarker, Patient, Safety, Ferdinand Magellan, FDA, Drug discovery, Organization, Neurodegenerative disease, AbbVie, Dopamine, Disease, Protein, Therapy, Acquisition, Merck, Letter, Glucocerebrosidase, GBA1, GLB1, University, Parkinson's disease, ALS, Plasma, Conference, Caraway, Pharmaceutical industry

In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.

Key Points: 
  • In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.
  • The dose escalation of the SAD phase is underway, and the MAD phase of the study is expected to begin in Q1 2024.
  • In 2023, we made several data presentations of results of our GBA1 program in preclinical models of Parkinson’s disease and Alzheimer’s disease.
  • Xavi is leaving the world of academia as a professor at the University of Barcelona and his part-time engagement with Gain to join a major pharmaceutical company.

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Retrieved on: 
Wednesday, January 31, 2024
Com, Psychosis, Dopamine, Patient, Serotonin, Depression, MDD, Mental health, Phase, Anhedonia, Citalopram, Patent, Prodrug, Pleasure, Pipamperone, Pharmaceutical industry

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Key Points: 
  • ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
    Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry.
  • The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
  • The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey.
  • At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression.

Relax'in Naturally Reinforces Mental Health

Retrieved on: 
Wednesday, January 31, 2024
Anxiety, Memory, Life, Sleep, Serotonin, Frasier, Depression, Mental disorder, Health, Dopamine, Brain, Mental, DSM-IV codes, Smoking, Tablet, GMP, Mental health, 5-Hydroxytryptophan, Pharmacist, WHO, Blister, Nursing

FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Mental health has been in the spotlight in recent years. As conditions like anxiety and depression become more common and diagnosable, it's important for consumers to have options to address them based on the severity of each case. With milder mental health concerns, solutions like Relax'in can help naturally restore a sense of peace and balance to everyday life.

Key Points: 
  • With milder mental health concerns, solutions like Relax'in can help naturally restore a sense of peace and balance to everyday life.
  • With mental health concerns on the rise, it's important for consumers to have options.
  • Restoring mental health balance with a natural alternative like Relax'in can also help avoid harmful habits rooted in mental instability, such as excessive alcohol consumption and smoking.
  • This ensures that Relax'in provides genuine, powerful, and natural support for those with mental health concerns.

Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Alternative Medicine, General Health, Health, Food, Beverage, Fitness & Nutrition, Retail, Other Health, EC50, Taste, Dopamine, Partex Group, Human, Gene, Serotonin, LOD, Blood pressure, Work, Aroma compound

Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.

Key Points: 
  • Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.
  • The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.
  • Olfactive Biosolutions biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules.
  • “Protenx is the culmination of years of work and the efforts of many Olfactive Biosolutions dedicated scientists,” said Dr. William Harries, the company’s chief scientist.

Clearmind Medicine Completed Type A Meeting with the FDA

Retrieved on: 
Wednesday, January 10, 2024
MEAI, CWY, Serotonin, DAT, Reward, NET, IND, Food, Dopamine, FDA, Therapy, Norepinephrine, Pharmaceutical industry

"We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Key Points: 
  • "We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • The active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.